Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2012.0223
EDITORIAL
|
Transcriptome mapping: ER-binding sites dynamics reveal new strategy for breast cancer biomarkers
|
Dimitrios H. Roukos, MD, PhD.
|
Affiliation: 1 Personalized Cancer Genomic Medicine, Ioannina University, Ioannina, Greece.
2 Department of Surgery, Ioannina University School of Medicine, Ioannina, 45110 Greece.
T: +302651007423, F: +302651007094
E-mail: droukos@uoi.gr |
Since there is no abstract available we provide the first paragraph.
Tamoxifen and aromatase inhibitors (AIs) save the lives of million of women with estrogen receptor (ER)- positive breast cancer. However, a substantial proportion of ER-positive breast cancer patients relapses and dies from the disease despite current treatment guidelines. Traditional biomedical research has not yet discovered biomarkers for predicting response to tamoxifen or other selective estrogen receptor modulator ( SERM ) and/or AIs. Transcriptome sequencing with next-generations sequencing (NGS) technologies provide now a novel strategy for discovering robust predictive tools. For the first time a new study published in Nature [1] is moving from cell lines and models to ER-positive patients' samples NGS-based analysis reveals the potential of discovering transcriptome tools that are capable of SERM or AIs response prediction.
(Citation: Gastric & Breast Cancer 2011; 11(2): 50-52)
|
|
| You can have an online full-text access and a PDF of this article: |
- Either purchase this paper for €35 EUR. Please, click here
|
|
- Or through one year subscription PayPal
|
|
Online
ISSN : 1109 - 7647
Print ISSN : 1109 - 7655
 We
subscribe to the HONcode principles. Verify
here.
please, read our policy about privacy
and confidentiality of information and transparency
of sponsorship
last
update: 23 April 2012 |
|
